Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Senzime AB (publ) stock

SEZI.ST
SE0002478776
A0X93V

Price

6.40
Today +/-
+0.01
Today %
+1.57 %
P

Senzime AB (publ) stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Senzime AB (publ) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Senzime AB (publ) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Senzime AB (publ) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Senzime AB (publ)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Senzime AB (publ) Stock Price History

DateSenzime AB (publ) Price
11/1/20246.40 undefined
10/31/20246.30 undefined
10/30/20246.30 undefined
10/29/20246.11 undefined
10/28/20246.31 undefined
10/25/20246.12 undefined
10/24/20245.99 undefined
10/23/20245.99 undefined
10/22/20246.08 undefined
10/21/20246.17 undefined
10/18/20246.05 undefined
10/17/20246.04 undefined
10/16/20246.17 undefined
10/15/20246.19 undefined
10/14/20246.41 undefined
10/11/20246.27 undefined
10/10/20246.36 undefined
10/9/20246.63 undefined
10/8/20246.73 undefined
10/7/20246.84 undefined

Senzime AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Senzime AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Senzime AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Senzime AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Senzime AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Senzime AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Senzime AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Senzime AB (publ)’s growth potential.

Senzime AB (publ) Revenue, EBIT and net profit per share

DateSenzime AB (publ) RevenueSenzime AB (publ) EBITSenzime AB (publ) Net Income
2027e581.22 M undefined94.08 M undefined82.29 M undefined
2026e328.44 M undefined30.6 M undefined23.12 M undefined
2025e183.6 M undefined-42.84 M undefined-34.68 M undefined
2024e75.48 M undefined-109.14 M undefined-104.04 M undefined
202335.75 M undefined-133.75 M undefined-134.15 M undefined
202214.03 M undefined-137.92 M undefined-132.7 M undefined
202110.98 M undefined-85.08 M undefined-82.14 M undefined
20209.34 M undefined-47.23 M undefined-47.44 M undefined
20196.71 M undefined-34.23 M undefined-32.72 M undefined
20183.21 M undefined-26.76 M undefined-25.62 M undefined
2017189,000 undefined-13.03 M undefined-13.03 M undefined
20161.63 M undefined-9.41 M undefined-9.41 M undefined
2015152,630 undefined-7.6 M undefined-7.58 M undefined
2014541,160 undefined-6.3 M undefined-6.19 M undefined
20131.24 M undefined-5.69 M undefined-5.6 M undefined
2012300,000 undefined-4.42 M undefined-4.39 M undefined
20110 undefined-2.11 M undefined-2.1 M undefined
20100 undefined-2.26 M undefined-2.35 M undefined
20090 undefined-1.63 M undefined-1.72 M undefined
20080 undefined-1.45 M undefined-1.64 M undefined
20070 undefined-100,000 undefined-240,000 undefined
20060 undefined-110,000 undefined-160,000 undefined
20050 undefined-150,000 undefined-220,000 undefined

Senzime AB (publ) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
000000001001036910143575183328581
--------------100.0050.0011.1140.00150.00114.29144.0079.2377.13
---------200.00--100.00--166.67-100.00-77.78-40.00-28.5722.86----
1000000-1-2-1-110-5-6-7-4-480000
000-1-1-2-2-4-5-6-7-9-13-26-34-47-85-137-133-109-423094
---------500.00---900.00--866.67-566.67-522.22-850.00-978.57-380.00-145.33-22.959.1516.18
000-1-1-2-2-4-5-6-7-9-13-25-32-47-82-132-134-104-342382
-----100.00-100.0025.0020.0016.6728.5744.4492.3128.0046.8874.4760.981.52-22.39-67.31-167.65256.52
2.332.664.716.546.637.459.3111.3512.811.6515.6728.3339.9244.775056.9863.3667.5592.270000
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Senzime AB (publ) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Senzime AB (publ) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
0.30.10.55.10.62.35.15.710.13.1414.4810.038.7432.6730.9160.3174.8726.04151.01
000000000.80.040.010.2102.732.533.294.944.218.57
00000000.20.113.260.250.480.670.830.655.875.645.584.82
0000.10000.20.50.360.490.371.060.962.443.958.8321.6520.34
0000.10.10.10.10.20.10.850.30.370.730.590.40.441.271.722.24
0.30.10.55.30.72.45.26.311.617.6515.5311.4611.237.7836.91173.8695.5659.2186.98
0.10.100.10.100000.010.030.050.240.180.662.873.1716.0714.52
00000000000000001.744.084.43
00000000000000005.424.750
9.310.612.917.720.323.326.4272728.6630.81143.71153.83158.7692.7681.473.39243.33227.19
00000000001.431.10.770.440.770.770.7700
00000000000000-00000
9.410.712.917.820.423.326.4272728.6732.27144.86154.84159.3894.1985.0484.48268.23246.15
9.710.813.423.121.125.731.633.338.646.3247.8156.31166.03197.16131.11258.89180.04327.43433.12
                                     
3.74.25.410.410.414.117.62227.627.5640.194.525.096.146.567.817.818.7414.96
001.16.74.16.38.510.524.937.7334.41130.66151.13201.18229.89397.55397.55636.73880.69
33.42.81.22.11.51.7-0.6-150-28.79000-126.48-174.02-254.79-383.56-520.18
00000000000-3.31-15.76-39.91000261.9375.48
0000000000000000000
6.77.69.318.316.621.927.831.937.565.2945.81131.87140.46167.41109.97231.35150.58523.81750.95
000.40.30.10.30.20.20.31.140.571.692.494.82.954.723.947.325.15
0.20.10.10.30.40.40.50.50.40.770.641.41.44.333.233.134.968.8211.91
00.300.20.20.22.40.20.20.20.240.230.561.151.175.452.063.353.61
0000000000000000000
000.10.20.70.30.30.10.100.040000.341.151.022.542.89
0.20.40.611.41.23.4112.121.483.314.4510.277.6814.4411.9822.0223.55
2.82.83.73.93.12.80.30.20.10.0400000.051.250.6210.518.58
0000000000020.6320.6219.4813.4111.869.7125.3621.77
00000000.1000.510.50.50001.742.893.75
2.82.83.73.93.12.80.30.30.10.040.5121.1321.1219.4813.4613.1112.0638.7534.1
33.24.34.94.543.71.31.12.151.9924.4425.5729.7521.1427.5524.0460.7857.64
9.710.813.623.221.125.931.533.238.667.4447.8156.31166.03197.16131.11258.89174.62584.58808.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Senzime AB (publ) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Senzime AB (publ)'s financial health and stability.

Assets

Senzime AB (publ)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Senzime AB (publ) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Senzime AB (publ) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Senzime AB (publ)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
000-1-1-2-2-4-5-6-7-9-13-26-34-48-84-133-137
000000000110051011101520
0000000000000000000
0000000-2010-103-4-1-10-202
000000001,00000000001,0001,0000
0000000000000000000
0000000000000000000
000-1-1-2-1-6-5-3-6-10-12-17-26-38-81-136-113
-2-1-2-4-2-3-3-1-1-3-4-6-10-9-30-2-5-7
-2-1-2-4-2-3-3-1-1-3-4-7-10-9-30-2-4-7
0000000000000000000
0000000000000000000
000000000000000-10-2-3
01210078811022122153291680100250
0021006781002212215128167092246
--------------2.00----5.00-
0000000000000000000
-1004-41204-611-4-123-1129-85-48124
-2.47-1.17-2.5-6.33-4.35-5.16-5-7.56-6.59-6.85-10.76-16.56-22.32-27.17-30.33-38.66-84.3-141.89-121.73
0000000000000000000

Senzime AB (publ) stock margins

The Senzime AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Senzime AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Senzime AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Senzime AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Senzime AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Senzime AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Senzime AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Senzime AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Senzime AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Senzime AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Senzime AB (publ) Margin History

Senzime AB (publ) Gross marginSenzime AB (publ) Profit marginSenzime AB (publ) EBIT marginSenzime AB (publ) Profit margin
2027e23.32 %16.19 %14.16 %
2026e23.32 %9.32 %7.04 %
2025e23.32 %-23.33 %-18.89 %
2024e23.32 %-144.59 %-137.84 %
202323.32 %-374.07 %-375.2 %
2022-31.32 %-982.73 %-945.56 %
2021-44.84 %-774.86 %-748.11 %
2020-84.6 %-505.84 %-508.13 %
2019-103.38 %-510.04 %-487.53 %
2018-162.63 %-832.64 %-797.17 %
2017-294.18 %-6,891.53 %-6,892.59 %
201667.69 %-578.07 %-578.13 %
2015-1,033.32 %-4,977.7 %-4,966.63 %
2014-323.22 %-1,163.67 %-1,144.15 %
2013-168.55 %-458.87 %-451.61 %
2012-396.67 %-1,473.33 %-1,463.33 %
201123.32 %0 %0 %
201023.32 %0 %0 %
200923.32 %0 %0 %
200823.32 %0 %0 %
200723.32 %0 %0 %
200623.32 %0 %0 %
200523.32 %0 %0 %

Senzime AB (publ) Stock Sales Revenue, EBIT, Earnings per Share

The Senzime AB (publ) earnings per share therefore indicates how much revenue Senzime AB (publ) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Senzime AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Senzime AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Senzime AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Senzime AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Senzime AB (publ) Revenue, EBIT and net profit per share

DateSenzime AB (publ) Sales per ShareSenzime AB (publ) EBIT per shareSenzime AB (publ) Earnings per Share
2027e5.13 undefined0 undefined0.73 undefined
2026e2.9 undefined0 undefined0.2 undefined
2025e1.62 undefined0 undefined-0.31 undefined
2024e0.67 undefined0 undefined-0.92 undefined
20230.39 undefined-1.45 undefined-1.45 undefined
20220.21 undefined-2.04 undefined-1.96 undefined
20210.17 undefined-1.34 undefined-1.3 undefined
20200.16 undefined-0.83 undefined-0.83 undefined
20190.13 undefined-0.68 undefined-0.65 undefined
20180.07 undefined-0.6 undefined-0.57 undefined
20170 undefined-0.33 undefined-0.33 undefined
20160.06 undefined-0.33 undefined-0.33 undefined
20150.01 undefined-0.48 undefined-0.48 undefined
20140.05 undefined-0.54 undefined-0.53 undefined
20130.1 undefined-0.44 undefined-0.44 undefined
20120.03 undefined-0.39 undefined-0.39 undefined
20110 undefined-0.23 undefined-0.23 undefined
20100 undefined-0.3 undefined-0.32 undefined
20090 undefined-0.25 undefined-0.26 undefined
20080 undefined-0.22 undefined-0.25 undefined
20070 undefined-0.02 undefined-0.05 undefined
20060 undefined-0.04 undefined-0.06 undefined
20050 undefined-0.06 undefined-0.09 undefined

Senzime AB (publ) business model

Senzime AB is a Swedish medical technology company specializing in the development, production, and marketing of products for monitoring the neuromuscular blockade state and preventing postoperative complications in patients. Founded in 2013, Senzime has become a major provider of medical devices on the global market. Its business model revolves around designing and producing intelligent monitoring devices that allow healthcare professionals to control important patient parameters during anesthesia and the postoperative phase. Senzime has developed various products for monitoring the neuromuscular blockade state, early detection of postoperative complications, and specialized use in intensive care medicine. The company is focused on continuous innovation and collaboration with healthcare professionals, universities, and research institutions to improve its technology and applications. Senzime aims to enhance patient safety and make treatment more effective and secure. Senzime AB (publ) is one of the most popular companies on Eulerpool.com.

Senzime AB (publ) SWOT Analysis

Strengths

Senzime AB (publ) prides itself on delivering high-quality products and innovative technology. The company's commitment to research and development enables them to offer advanced medical devices and solutions that meet the needs of healthcare professionals and patients.

Senzime AB (publ) has successfully established a strong market presence in the medical device industry. The company's brand reputation, customer trust, and global distribution network contribute to its competitive advantage. This solid market position helps attract new customers and retain existing ones.

Weaknesses

Senzime AB (publ) relies heavily on specific market segments for its revenue generation. Any downturn or disruption in these markets could potentially impact the company's financial performance. Actively diversifying into new healthcare sectors could help mitigate this weakness.

As a relatively small company, Senzime AB (publ) may face resource constraints in terms of capital, marketing, and distribution capabilities. This could limit the company's ability to compete with larger players in the industry. However, the company's agility and focus on niche markets can also be seen as an advantage.

Opportunities

The global medical device market is experiencing significant growth due to increasing healthcare expenditure, aging population, and advancements in technology. Senzime AB (publ) is well-positioned to capitalize on this opportunity by expanding its product portfolio and entering new markets.

Forming strategic partnerships and collaborations with leading technology companies or healthcare institutions can provide Senzime AB (publ) with access to new technologies, expertise, and resources. This can facilitate product development and enhance the company's competitive advantage.

Threats

The medical device industry is highly competitive, with numerous established players and new entrants. Senzime AB (publ) faces the risk of competitors offering similar products, effectively capturing market share, or engaging in aggressive pricing strategies. Continuous innovation and differentiation are crucial to mitigate this threat.

Operating in the medical device sector requires strict adherence to regulatory standards and compliance with various healthcare regulations. Changes in regulations or failure to comply might lead to delayed product approvals, increased costs, or reputational damage. Senzime AB (publ) must stay updated and ensure compliance to minimize such risks.

Senzime AB (publ) Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Senzime AB (publ) historical P/E ratio, EBIT multiple, and P/S ratio

Senzime AB (publ) shares outstanding

The number of shares was Senzime AB (publ) in 2023 — This indicates how many shares 92.27 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Senzime AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Senzime AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Senzime AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Senzime AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Senzime AB (publ).

Senzime AB (publ) latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.2 -0.28  (-37.25 %)2024 Q2
3/31/2024-0.31 -0.23  (24.84 %)2024 Q1
12/31/2023-0.31 -0.33  (-7.84 %)2023 Q4
9/30/2023-0.31 -0.33  (-7.84 %)2023 Q3
6/30/2023-0.34 -0.42  (-24.78 %)2023 Q2
12/31/2019-1.62 -0.18  (88.9 %)2019 Q4
9/30/20190 -0.15  (0 %)2019 Q3
6/30/20190 -0.17  (0 %)2019 Q2
1

Eulerpool ESG Scorecard© for the Senzime AB (publ) stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

25

👫 Social

57

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Senzime AB (publ) shareholders

%
Name
Stocks
Change
Date
17.84265 % Crafoord Family20,222,151775,1006/30/2024
11.29674 % Segulah AB12,803,2717,390,0006/30/2024
6.68065 % Fj¿rde AP-Fonden7,571,5781,200,0006/30/2024
6.00334 % Rapp (Fredrik)6,803,94606/30/2024
5.24936 % Handelsbanken Kapitalf¿rvaltning AB5,949,416-1,762,78510/21/2024
4.29092 % TIN Fonder4,863,15706/30/2024
3.83394 % Swedbank Robur Fonder AB4,345,23606/30/2024
3.44591 % Carnegie Fonder AB3,905,46106/30/2024
1.81684 % FCG Fonder AB2,059,138-17,9728/31/2024
0.84027 % Amundi Asset Management, SAS952,324566,7838/31/2024
1
2

Senzime AB (publ) Executives and Management Board

Dr. Sorin Brull(67)
Senzime AB (publ) Director
Compensation 1.22 M
Dr. Jenny Freeman(69)
Senzime AB (publ) Director
Compensation 643,000
Mr. Philip Siberg(50)
Senzime AB (publ) Chief Executive Officer (since 2015)
Compensation 450,000
Mr. Adam Dahlberg(50)
Senzime AB (publ) Chairman of the Board (since 2000)
Compensation 210,000
Mr. Lennart Kalen(76)
Senzime AB (publ) Independent Director
Compensation 210,000
1
2
3

Senzime AB (publ) Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AddLife B Stock
AddLife B
SupplierCustomer0,760,430,710,740,37-0,23
Fukuda Denshi Stock
Fukuda Denshi
SupplierCustomer0,48-0,460,320,620,550,06
Svenska Handelsbanken A Stock
Svenska Handelsbanken A
SupplierCustomer0,45-0,07-0,340,270,26-0,24
Bank of New York Mellon Stock
Bank of New York Mellon
SupplierCustomer0,250,210,400,640,11-0,28
1

Most common questions regarding Senzime AB (publ)

What values and corporate philosophy does Senzime AB (publ) represent?

Senzime AB (publ) represents values of innovation, quality, and patient safety. As a leading medical technology company, Senzime is dedicated to improving healthcare by providing advanced monitoring solutions. The company focuses on developing innovative products that enhance the accuracy and reliability of patient data, enabling healthcare professionals to make informed decisions. Senzime's corporate philosophy revolves around a patient-centric approach, ensuring the highest level of care and safety for individuals undergoing surgery or other medical procedures. With a strong commitment to excellence and a focus on improving patient outcomes, Senzime AB (publ) is a trusted name in the medical technology industry.

In which countries and regions is Senzime AB (publ) primarily present?

Senzime AB (publ) is primarily present in various countries and regions globally. The company has a strong presence in Europe, including Sweden, Germany, France, and the United Kingdom. Additionally, Senzime has expanded its reach to other parts of the world, including the United States, China, Japan, and several countries in the Middle East. With its growing international presence, Senzime AB (publ) aims to offer its innovative medical technology solutions and products to healthcare providers and patients worldwide.

What significant milestones has the company Senzime AB (publ) achieved?

Senzime AB (publ) has achieved several significant milestones. The company successfully launched the TetraGraph® monitoring system, a pioneering device for neuromuscular monitoring. Senzime AB (publ) has also gained regulatory approvals for the TetraGraph® system in various markets, including the European Union and the United States. Moreover, they have secured partnerships and collaborations with leading medical institutions to enhance the adoption of their innovative technologies. In addition, Senzime AB (publ) has received prestigious awards and recognitions for their groundbreaking solutions in the field of patient monitoring. These milestones demonstrate the company's commitment to revolutionizing healthcare through advanced and effective medical devices.

What is the history and background of the company Senzime AB (publ)?

Senzime AB (publ) is a Swedish medical technology company founded in 2010. Specializing in patient monitoring solutions, the company focuses on improving clinical outcomes and enhancing healthcare efficiency. Senzime AB (publ) offers innovative products such as TetraGraph, a neuromuscular monitoring system, and OnZurf, a continuous glucose monitoring system. With a strong commitment to research and development, Senzime AB (publ) has evolved into a leading provider of advanced medical devices globally. Their cutting-edge technology and dedication to improving patient care have positioned Senzime AB (publ) as a reliable and trusted name in the healthcare industry.

Who are the main competitors of Senzime AB (publ) in the market?

Senzime AB (publ) faces competition in the market from various companies. Some of the main competitors of Senzime AB (publ) include Medtronic, GE Healthcare, Philips Healthcare, and Masimo Corporation. These companies also provide innovative medical devices and solutions for patient monitoring and anesthesia. Senzime AB (publ) competes by offering its unique product portfolio, including the TetraGraph neuromuscular monitoring system, which provides accurate and reliable data for monitoring patients' response to anesthesia. The company's focus on advancing patient safety and enhancing surgical outcomes sets them apart from their competitors in the market.

In which industries is Senzime AB (publ) primarily active?

Senzime AB (publ) is primarily active in the medical technology industry.

What is the business model of Senzime AB (publ)?

The business model of Senzime AB (publ) is focused on the development and commercialization of medical technology products for monitoring patients during surgeries. Senzime offers innovative solutions that enable healthcare professionals to accurately assess and manage patients' physiological responses in real-time, providing valuable data for improved patient care and outcomes. Senzime's flagship product is the TetraGraph, a neuromuscular monitoring system that helps in measuring the patient's muscle function and depth of blockade during anesthesia. By delivering advanced monitoring solutions, Senzime aims to enhance patient safety and optimize anesthesia management in healthcare settings.

What is the P/E ratio of Senzime AB (publ) 2024?

The Senzime AB (publ) P/E ratio is -5.68.

What is the P/S ratio of Senzime AB (publ) 2024?

The Senzime AB (publ) P/S ratio is 7.82.

What is the Quality Investing of Senzime AB (publ)?

The Quality Investing for Senzime AB (publ) is 7/10.

What is the revenue of Senzime AB (publ) 2024?

The expected Senzime AB (publ) revenue is 75.48 M SEK.

How high is the profit of Senzime AB (publ) 2024?

The expected Senzime AB (publ) profit is -104.04 M SEK.

What is the business model of Senzime AB (publ)

Senzime AB (publ) is a Swedish medical technology company that focuses on innovative systems for monitoring anesthesia and postoperative stress in patients. It was founded in 2008 and is headquartered in Uppsala. The company's business model focuses on the development, manufacturing, and marketing of medical products that aim to meet the clinical need for improved monitoring systems. Senzime currently offers two main products: the TetraGraph® system and the CliniSenz® system. The TetraGraph® system is a non-invasive monitoring system that monitors the neuromuscular blockade state of patients during anesthesia using electromyographic signals (EMG). The system monitors the patient's muscle activity to determine the timing of extubation and enable a more effective and safe removal of ventilation devices. The TetraGraph system can also be used to avoid potential muscle overstimulation from surgical devices that may harm the lungs or respiratory muscles. The CliniSenz® system is a non-invasive system for monitoring the body's postoperative stress. It consists of a bioelectrical sensor attached to the patient's skin that continuously monitors electromyographic signals, heart rate, and blood oxygen levels. By monitoring these parameters, doctors can determine the best time to administer pain medication or start rehabilitation. Monitoring heart rate can also help doctors identify if the patient is experiencing overload and adjust treatment accordingly. Senzime has a unique business strategy based on partnerships with leading hospital chains, anesthesiologists, and intensive care physicians worldwide, as well as collaboration with other companies in the field of medical device development and marketing. Its goal is to sell the TetraGraph and CliniSenz systems in both Europe and the United States and increase market share by focusing on hospitals and clinics. The company is committed to expanding its technology into other areas of healthcare by investing in research and development of new products. It is seeking marketing and distribution partners to sell its products globally and raise brand awareness. The focus is on developing innovative medical devices that can contribute to more efficient healthcare and provide better patient care. In summary, Senzime relies on innovative technologies to improve patient monitoring during and after surgery. Its business model focuses on the development and marketing of medical products through partnerships with leading hospitals and clinic chains. The company has a unique position in the market and continues to invest in the development of new products.

What is the Senzime AB (publ) dividend?

Senzime AB (publ) pays a dividend of 0 SEK distributed over payouts per year.

How often does Senzime AB (publ) pay dividends?

The dividend cannot currently be calculated for Senzime AB (publ) or the company does not pay out a dividend.

What is the Senzime AB (publ) ISIN?

The ISIN of Senzime AB (publ) is SE0002478776.

What is the Senzime AB (publ) WKN?

The WKN of Senzime AB (publ) is A0X93V.

What is the Senzime AB (publ) ticker?

The ticker of Senzime AB (publ) is SEZI.ST.

How much dividend does Senzime AB (publ) pay?

Over the past 12 months, Senzime AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Senzime AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Senzime AB (publ)?

The current dividend yield of Senzime AB (publ) is .

When does Senzime AB (publ) pay dividends?

Senzime AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Senzime AB (publ)?

Senzime AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Senzime AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Senzime AB (publ) located?

Senzime AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Senzime AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Senzime AB (publ) from 11/4/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did Senzime AB (publ) pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of Senzime AB (publ) in the year 2023?

In the year 2023, Senzime AB (publ) distributed 0 SEK as dividends.

In which currency does Senzime AB (publ) pay out the dividend?

The dividends of Senzime AB (publ) are distributed in SEK.

All fundamentals about Senzime AB (publ)

Our stock analysis for Senzime AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Senzime AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.